BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29101112)

  • 21. Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
    Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
    JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    Vietri MT; D'Elia G; Caliendo G; Resse M; Casamassimi A; Passariello L; Albanese L; Cioffi M; Molinari AM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
    Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
    J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
    Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
    Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
    J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
    Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial prostate cancer.
    Giri VN; Beebe-Dimmer JL
    Semin Oncol; 2016 Oct; 43(5):560-565. PubMed ID: 27899188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.
    Margel D; Benjaminov O; Ozalvo R; Shavit Grievink L; Kedar I; Yerushalmi R; Ben-Aharon I; Neiman V; Yossepowitch O; Kedar D; Levy Z; Shohat M; Brenner B; Baniel J; Rosenbaum E
    BMC Cancer; 2014 Jul; 14():528. PubMed ID: 25047061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline genetics of prostate cancer.
    Khan HM; Cheng HH
    Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
    Cimadamore A; Lopez-Beltran A; Massari F; Santoni M; Mazzucchelli R; Scarpelli M; Galosi AB; Cheng L; Montironi R
    Future Oncol; 2020 Feb; 16(5):75-80. PubMed ID: 31916449
    [No Abstract]   [Full Text] [Related]  

  • 36. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
    Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.
    Darst BF; Hughley R; Pfennig A; Hazra U; Fan C; Wan P; Sheng X; Xia L; Andrews C; Chen F; Berndt SI; Kote-Jarai Z; Govindasami K; Bensen JT; Ingles SA; Rybicki BA; Nemesure B; John EM; Fowke JH; Huff CD; Strom SS; Isaacs WB; Park JY; Zheng W; Ostrander EA; Walsh PC; Carpten J; Sellers TA; Yamoah K; Murphy AB; Sanderson M; Crawford DC; Gapstur SM; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas C; Kittles RA; Xu J; Stern MC; Chokkalingam AP; Multigner L; Parent ME; Menegaux F; Cancel-Tassin G; Kibel AS; Klein EA; Goodman PJ; Stanford JL; Drake BF; Hu JJ; Clark PE; Blanchet P; Casey G; Hennis AJM; Lubwama A; Thompson IM; Leach RJ; Gundell SM; Pooler L; Mohler JL; Fontham ETH; Smith GJ; Taylor JA; Brureau L; Blot WJ; Biritwum R; Tay E; Truelove A; Niwa S; Tettey Y; Varma R; McKean-Cowdin R; Torres M; Jalloh M; Magueye Gueye S; Niang L; Ogunbiyi O; Oladimeji Idowu M; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Yeboah ED; Mensah JE; Anthony Adjei A; Diop H; Cook MB; Chanock SJ; Watya S; Eeles RA; Chiang CWK; Lachance J; Rebbeck TR; Conti DV; Haiman CA
    Eur Urol; 2022 May; 81(5):458-462. PubMed ID: 35031163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
    Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.